Clinical Trials for Colon Cancer

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-C*08:02-positive, KRAS G12D-mutant unresectable advanced or metastatic solid tumors who have received at least one approved systemic regimen and have no curative option receive a single infusion of NT-112, an autologous TCR-engineered T-cell therapy targeting KRAS G12D presented by HLA-C*08:02. Treatment includes lymphodepletion before infusion and a short course of interleukin-2 afterward.

ClinicalTrials.gov ID: NCT06218914

An Open-label Phase 1 Study to Investigate SGN-CEACAM5C in Adults With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed, refractory, or progressive unresectable or metastatic solid tumors, including colorectal, gastric/gastroesophageal junction, pancreatic, and lung cancers, receive PF-08046050, a CEACAM5-targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor. Previously treated colorectal adenocarcinoma cohorts receive PF-08046050 with bevacizumab.

ClinicalTrials.gov ID: NCT06131840

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive intravenous MDX2001 monotherapy. MDX2001 is an investigational tetraspecific antibody that binds c-MET and TROP2 on tumors while engaging CD3 and providing CD28 costimulation to promote tumor-directed T-cell activity.

ClinicalTrials.gov ID: NCT06239194

A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or recurrent solid tumors that have progressed after prior treatment and lack suitable standard options receive [225Ac]-FPI-2068, an investigational EGFR/c-MET-targeted alpha-emitting radioimmunotherapy. A nonradioactive FPI-2053 antibody predose is used to optimize biodistribution, with [111In]-FPI-2107 SPECT imaging used to assess uptake and dosimetry.

ClinicalTrials.gov ID: NCT06147037

A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with measurable, unresectable or metastatic KRAS G12D-mutant solid tumors, ECOG 0–1, and at least one prior systemic chemotherapy regimen receive oral debecarasib (LY3962673), a mutant-selective inhibitor of GDP-bound KRAS G12D. Treatment is given alone or with cetuximab or chemotherapy agents.

ClinicalTrials.gov ID: NCT06586515

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with locally advanced or metastatic solid tumors who have exhausted or are unsuitable for standard treatment receive oral OKN4395, an investigational EP2/EP4/DP1 prostanoid receptor antagonist, alone or with the anti–PD-1 antibody pembrolizumab. Expansion cohorts give OKN4395 alone for selected sarcomas and pancreatic adenocarcinoma, and the combination for NSCLC, microsatellite-stable or MSI-low colorectal cancer, and head and neck squamous cell carcinoma.

ClinicalTrials.gov ID: NCT06789172

A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable, unresectable or metastatic colorectal, non-small-cell lung, or gastric cancer and ECOG performance status 0–1 receive BMS-986490 alone or with bevacizumab. BMS-986490 is a CEACAM5-targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan; bevacizumab targets VEGF.

ClinicalTrials.gov ID: NCT06730750

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated unresectable or metastatic KRAS G12D–mutated solid tumors are eligible for dose escalation; dose expansion is limited to pancreatic ductal adenocarcinoma after at least one prior systemic therapy. All receive IV ARV-806, an investigational PROTAC designed to degrade mutant KRAS G12D, weekly or every two weeks.

ClinicalTrials.gov ID: NCT07023731

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with metastatic, refractory gastrointestinal, hepatobiliary, genitourinary, breast, ovarian, endometrial, or selected endocrine/neuroendocrine tumors who have failed standard therapies and have a resectable lesion for TIL generation. Treatment includes lymphodepleting chemotherapy, autologous tumor-infiltrating lymphocyte (TIL) infusion, high-dose aldesleukin, and pembrolizumab, a PD-1 immune checkpoint inhibitor, with timing of pembrolizumab varying by study arm.

ClinicalTrials.gov ID: NCT01174121

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors who have exhausted, are ineligible for, or decline standard therapy receive IV AGX101 in dose-escalation or expansion cohorts, including a planned advanced angiosarcoma cohort. AGX101 is an antibody–drug conjugate targeting TM4SF1 on tumor cells and tumor-associated blood vessels that delivers a maytansinoid tubulin inhibitor.

ClinicalTrials.gov ID: NCT06440005